Merck MRK, along with its partner Eisai, announced that the phase III LITESPARK-012 study, which evaluated Keytruda-based ...

Merck & Co (MSD) and Eisai’s combination therapies failed to meet the dual primary endpoints of progression-free survival ...

After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect ...

Merck and Eisai provide update on phase 3 LITESPARK-012 trial evaluating first-line combination treatments for certain patients with advanced RCC: Rahway, New Jersey Wednesday, Ap ...

Shares of Kura Oncology KURA rose 8% after the company announced encouraging preliminary data from the ongoing FIT-001 study evaluating darlifarnib in combination with cabozantinib. The analysis ...

India: A recent study published in Apollo Medicine has shed light on the demographic patterns and histomorphological ...

KEYNOTE-564 follow-up shows OS and DFS gains with adjuvant pembrolizumab in high-risk ccRCC, plus guidance on relapse after therapy. In the adjuvant setting, managing the patient with high-risk clear ...

Select patients with oligometastatic ccRCC might be managed with a period of metastasis-directed therapy alone. Serial metastasis-directed radiation therapy may delay systemic therapy in clear cell ...

In a phase 3 trial, adding adjuvant belzutifan to standard of care pembrolizumab reduces the chances of clear cell RCC recurrence after nephrectomy, but overall survival data are still immature.

RNA modification has a role in cancer progression, including renal cell carcinomas (RCCs). Recent work showed that KIAA1429, which serves as a scaffold for the m6A methyltransferase holocomplex, is ...